Table 1.
Streotactic body radiotherapy for oligo-recurrence within nodal area in colorectal cancer
| Ref. | Study year | No. of patients | Proportion of oligo-nodal metastases | SBRTdose (Gy)1; range (median) |
Outcomes |
||
| LC | OS | Severe GI toxicity | |||||
| Bae et al[69] | 2012 | 41 | 44% | 45-60 (48) | 57% (5 yr) | 38% (5 yr) | 7% |
| Kang et al[68] | 2010 | 59 | 53% | 36-51 (42) | 24% (5 yr) | 29% (5 yr) | 3% |
| Kim et al[55] | 2009 | 7 | 100% | 36-51 (48) | (-) | 71% (3 yr) | 14% |
| Kim et al[75] | 2008 | 23 | 100% | 30-51 (39) | 74% (4 yr) | 25% (4 yr) | 4% |
| Hoyer et al[66] | 2006 | 64 | 5% | 45 (45) | 63% (2 yr) | 38% (2 yr) | 5% |
1
Three fractions of streotactic body radiotherapy were used in all studies. LC: Local control; OS: Overall survival; GI: Gastrointestinal.